PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS was delisted on the 2nd of November, 2022.
60 hedge funds and large institutions have $84.3M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 18 increasing their positions, 14 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
38% more capital invested
Capital invested by funds: $61.1M → $84.3M (+$23.2M)
29% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 14
20% more funds holding
Funds holding: 50 → 60 (+10)
13% more call options, than puts
Call options by funds: $89K | Put options by funds: $79K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$409K |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
+$391K |
| 3 |
Morgan Stanley
New York
|
+$337K |
| 4 |
Millennium Management
New York
|
+$270K |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
+$193K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$1.65M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$280K |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$247K |
| 4 |
Renaissance Technologies
New York
|
-$140K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$137K |
PHAS Hedge Fund Activity: Q2 2020 in Review
60 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) for Q2 2020, worth a combined $84.3M — up 38% from $61.1M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PHAS positions and 9 closed out — a net gain of 10 holders — while 18 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $409K. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $1.65M sold.
- 60 institutional investors held PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) as of Q2 2020, up from 50 in Q1 2020.
- Funds reported $84.3M of PhaseBio Pharmaceuticals, Inc. Common Stock stock for Q2 2020, up 38% quarter-over-quarter.
- 19 funds opened new PhaseBio Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 9 closed out, a net change of +10 holders.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was BlackRock, an estimated $409K added.
- The largest PhaseBio Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Ghost Tree Capital, an estimated $1.65M sold.
Based on aggregated 13F filings for Q2 2020.